Davide Capodanno ✓

@DFCapodanno · Catania, Sicily · joined 06 Mar 2019

Professor of Cardiology at University of Catania, Italy. Editor-in-Chief of @EuroInterventio.

22 945Followers

697Following

2 494Posts total

94.7KViews on collected posts

Against accounts of the same size

11 posts from the last 90 days, next to the 10K–100K follower range. ordinary reach for its size, weaker reaction than most.

Median views1 521this account2 043median for 10K–100K

Reach, %6.63%this account6.16%median for 10K–100K

Engagement, %0.42%this account1.59%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	1 521	2 043	0.74×
Reach (views ÷ followers)	6.63%	6.16%	1.08×
Engagement rate	0.42%	1.59%	0.26×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

15.7K23 Aug

33.4K26 Aug

1.5K

717

44527 Aug

6K29 Aug

4.5K30 Aug

29.5K31 Aug

1.3K

6171 Sep

Last 11 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.71%23 Aug

1.02%26 Aug

0.13%

0.42%

0.22%27 Aug

1.42%29 Aug

1.68%30 Aug

1.42%31 Aug

0.29%

0.08%

0.00%1 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.59%.

What the audience does

Likes54.1%887 in total

Reposts16.6%273 in total

Replies1.5%25 in total

Quotes1.0%16 in total

Bookmarks26.8%439 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

Followers by day

4 Sep

Daily snapshots since 04 Sep 2026; the dashed line is the starting count.

Latest posts

@DFCapodanno What about Pulnovo’s PADN study? Sounds a lot more game-changing that of these… 617 views · 0 likes · 0 reposts · 0 replies 01 Sep 2026 @DFCapodanno Incredible volume. 1.3K views · 1 likes · 0 reposts · 0 replies 31 Aug 2026 @DFCapodanno congrats to everyone behind these trials simultaneous NEJM publications like this dont happen by accident thats a lot of coordinated work 1K views · 3 likes · 0 reposts · 0 replies 31 Aug 2026 An incredible number of trials published simultaneously in the NEJM: I honestly can’t quite wrap my head around what is happening. Congratulations to everyone involved. It was difficult to choose only five trials, but these are the ones I selected for the interventional https://t 29.5K views · 311 likes · 101 reposts · 5 replies 31 Aug 2026 SWITCH-SWEDEHEART is a comparison between policies, not between drugs. The policy-recommended agent was dispensed to 75.8% of patients in the ticagrelor-policy group and 60.6% of those in the prasugrel-policy group. Why did patients in the prasugrel-policy group experience less 4.5K views · 55 likes · 16 reposts · 3 replies 30 Aug 2026 EPIDAURUS was stopped for safety reasons: ticagrelor and prasugrel cause more bleeding than clopidogrel in atrial fibrillation patients undergoing PCI, and so far, there is nothing particularly surprising about that. But at this point, are we perhaps asking the wrong question? ht 6K views · 66 likes · 15 reposts · 2 replies 29 Aug 2026 @DFCapodanno Interesting take. LAAO is associated with a significant reduction in bleeding events and would be a favourable approach in HBR patients, especially those with CKD. The clinical meaningful absolute excess is low for ischemic stroke risk 0.5% (1/PY), using a Bayesian. 445 views · 1 likes · 0 reposts · 0 replies 27 Aug 2026 @DFCapodanno Solid review. Implementation's the bottleneck though, not enough centres doing LAAC proficiently and the training pipeline is thin. Same old story. 717 views · 2 likes · 1 reposts · 0 replies 26 Aug 2026 @DFCapodanno @gcfmd Seems counterintuitive that LAAO increased non procedural bleeding risk? 1.5K views · 1 likes · 0 reposts · 1 replies 26 Aug 2026 No free lunch. In our meta-analysis, now published in JAMA Cardiology, transcatheter left atrial appendage closure (LAAC) was associated with similar long-term risks of any stroke and major bleeding compared with oral anticoagulation in patients with atrial fibrillation, while ht 33.4K views · 250 likes · 78 reposts · 8 replies 26 Aug 2026 The 10 trials I am most looking forward to at the ESC Hot Lines next week (in no particular order): LIBREXIA-ACS, where milvexian could end up like apixaban in APPRAISE-2, perhaps with less bleeding. Rivaroxaban did not exactly have an easy story after ATLAS ACS 2 either, https: 15.7K views · 197 likes · 62 reposts · 6 replies 23 Aug 2026